Trellus Health PLC Notice of Results (1931L)
09 Septiembre 2021 - 1:00AM
UK Regulatory
TIDMTRLS
RNS Number : 1931L
Trellus Health PLC
09 September 2021
Trellus Health plc
("Trellus Health" or the "Company")
Notice of Interim Results
LONDON, UK. AND NEW YORK, U.S. (9 September 2021). Trellus
Health plc (AIM: TRLS), which is commercialising a scientifically
validated, resilience-based, connected health solution for chronic
condition management, announces that its maiden interim results for
the six month period ended 30 June 2021 will be released on
Wednesday 22 September 2021.
Analyst Briefing
A briefing open to analysts will take place remotely via video
conference call on Wednesday 22 September at 1.00pm (BST). If you
would like the details of this call please contact Walbrook PR on
trellus@walbrookpr.com.
Investor Presentation
Monique Fayad, Chief Executive Officer, Marla Dubinsky,
Co-Founder and Salim Hamir, Company Secretary and Chief Financial
Officer, will provide a live presentation relating to the interim
results via the Investor Meet Company platform on Wednesday 22
September 2021 at 4.30pm (BST).
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Trellus Health plc via:
https://www.investormeetcompany.com/trellus-health-plc/register-investor
Investors who already follow Trellus Health plc on the Investor
Meet Company platform will automatically be invited.
For further information please contact:
Trellus Health plc www.trellushealth.com
M onique Fayad , CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser Tel: 020 7496 3000
& Broker)
Aubrey Powell / Jen Boorer /Hannah
Woodley
Walbrook PR Limited Tel: 020 7933 8780 or trellus@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About Trellus Health plc (www.trellushealth.com)
Trellus Health (LSE: TRLS) is a leading pioneer in
resilience-driven care and the first digital health company focused
on the intersection of chronic physical conditions and mental
health. Trellus Health's digital-first chronic care management
solution integrates convenient access to a licensed
multidisciplinary care team with a suite of tools for resilience
assessment, education and behavior modification, remote monitoring,
health maintenance and prevention. Through its TrellusElevate(TM)
connected care platform and companion App, the Company coordinates
expert whole-person care, addressing both clinical and behavioral
health together, in context, to improve outcomes and reduce
healthcare costs for patients, employers, and the healthcare
system.
Trellus Health is commercialising the provision of digital
chronic condition management solutions for employers and health
plans that utilise the scientifically validated resilience-based
methodology and a proprietary HIPAA-compliant technology platform
called TrellusElevate(TM) to coordinate and deliver personalised
care remotely via telehealth. The Company is initially focused on
Inflammatory bowel disease ("IBD"), which includes the chronic
incurable conditions of Crohn's Disease and ulcerative colitis, but
considers its approach to have potential utility and demand across
many chronic conditions.
The TrellusElevate(TM) platform is the Company's proprietary
connected health platform that incorporates the proprietary
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. The proprietary methodology and resilience-driven
multidisciplinary care model have been scientifically validated to
demonstrate meaningful improvements in patient outcomes and over 85
per cent. reduction in unplanned healthcare utilisation (emergency
department visits and hospitalisations) which the directors of the
Company believe indicates the potential for significant cost
savings for healthcare payers.
The Company was founded by Dr. Marla C. Dubinsky, MD and Dr.
Laurie Keefer, PhD, both with decades of combined experience in IBD
and psychogastroenterology, respectively. Trellus Health's
patent-pending GRITT(TM) resilience assessment and personalized
treatment methodology was developed and validated at the Mount
Sinai Health System to build resilience and wellness for improved
outcomes at lower cost.
Shares in Trellus Health were admitted to trading on AIM in May
2021, under the ticker TRLS. For more information on Trellus
Health, visit www.trellushealth.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFVLLBFKLXBBQ
(END) Dow Jones Newswires
September 09, 2021 02:00 ET (06:00 GMT)
Trellus Health (LSE:TRLS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Trellus Health (LSE:TRLS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024